Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Belviq Adverse Events

|Includes: Arena Pharmaceuticals, Inc. (ARNA)

The data from July 1st through September 30th (Q3 of last year) is finally up in a readable fashion from FDAble.com. This would represent the adverse events related to prescription sales of about 48,000 scripts. There were 8 events involving the name Belviq, and 1 event involving the name lorcaserin.

Below are the events:

  • In case 9519128 Belviq was identified as the primary suspect. The patient was a 73 year old female. The patient complained of abasia, asthenia, balance disorder, a decrease in blood glucose, dry mouth, dysphonia, fatigue, fear, hypophagia, impared driving ability, and polydypsia.
  • In case 9524869 Belviq was identified as the primary suspect. The patient was a 46 year old female. The patient complained that the drug was ineffective and headche.
  • In case 9438727 Belviq was identified as the primary suspect. The patient was female. The patient complained that the drug caused a disturbance in attention, caused a euphoric mood, and made her feel drunk.
  • In case 9456691 Belviq was identified as the primary suspect. The patient was a 72 year old male. The patient complained of abnormal dreams, back pain, cough, depression, dizziness, dry mouth, fatigue, head ache, and insomnia.
  • In case 9460819 Belviq was identified as the primary suspect. The patient was a 49 year old female. The patient complained of aggression, agitation, anger, confused state, depression, disturbance in attention, facial spasm, headache, nausea, suicidal ideation, blurred vision and vomiting.
  • In case 9472852 Belviq was identified as the primary suspect. The patient was a 52 year old male. The patient complained of euphoric mood.
  • In case 9535951 Belviq was identified as the primary suspect. The patient was a 54 year old female. The patient complained of asthenia, confusional state, coordination abnormal, disturbance in attention, fatigue, headache, musculoskelatal stiffness, abnormal thinking, and blurred vision.
  • In case 9549531 Belviq was identified as the primary suspect. The patient was female and required hospitalization. The patient complained of increased blood pressure and paraesthesia.
  • In case 9490915 Belviq was identified as a secondary suspect. The patient was a 39 year old female. The patient complained of abdominal discomfort, chest discomfort, dizziness, dyspnoea, fatigue, feeling abnormal, headache, insomnia, nausea, and pruritus.

Disclosure: The author is long ARNA.